Medicine and Dentistry
Homologous Recombination
100%
Chemotherapy
100%
Cells
83%
DNA Damage
50%
DNA Repair
33%
Mitoxantrone
33%
Non-Homologous End Joining
33%
Gyrase Inhibitor
33%
Gene Targeting
33%
Malignant Neoplasm
33%
Ovarian Cancer
16%
DNA Topoisomerase (ATP Hydrolysing)
16%
Low Drug Dose
16%
Imatinib
16%
Ovarian Cancer Cell Line
16%
Development
16%
Cell Line
16%
Cell Cycle
16%
Protein Tyrosine Kinase
16%
Tenidap
16%
Programmed Cell Death
16%
Diseases
16%
Tumor Cell
16%
Stress
16%
Pharmacology, Toxicology and Pharmaceutical Science
Antibiotic Resistance
100%
Prevalence
60%
Gyrase Inhibitor
33%
Mitoxantrone
33%
Malignant Neoplasm
33%
Commensal Escherichia Coli
20%
Normal Human
20%
Imatinib
16%
Protein Tyrosine Kinase
16%
Ovary Cancer
16%
Diseases
16%
DNA Topoisomerase (ATP Hydrolysing)
16%
Tenidap
16%
Oxytetracycline
10%
Streptomycin
10%
Cotrimoxazole
10%
Chloramphenicol
10%
Cefotaxime
10%
Enterobacteriaceae
10%
Ciprofloxacin
10%
Ampicillin
10%
Tetracycline
10%
Nalidixic Acid
10%
Element
10%
Trimethoprim
10%
Bacterium
10%
Public Health Policy
10%
Antibiotic Agent
10%
Biochemistry, Genetics and Molecular Biology
Homologous Recombination
100%
DNA Damage
50%
Gene Targeting
33%
DNA Repair
33%
Non-Homologous End Joining
33%
Cancer Cell
16%
Cell Cycle
16%
Development
16%
Imatinib
16%
Stress
16%
Apoptosis
16%
Low Drug Dose
16%
